GlassScriptPhysician profile
Amanda Behnen
NPI 1356900492
$7,123.67
in general payments reported to CMS, 2019-2025
25 companies · $1,621 in 2025
The $1,621 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $159 · 2022: $1,178 · 2023: $1,793 · 2024: $2,372 · 2025: $1,621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,618 · Education: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,617.78 |
| Education | $168.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,151.09 | 2022-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $913.39 | 2023-2024 | Vtama |
| Leo Pharma INC. | $840.87 | 2022-2025 | Adbry, Anzupgo |
| Abbvie INC. | $744.34 | 2022-2024 | |
| Ucb, INC. | $627.95 | 2023-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $573.92 | 2021-2025 | Aklief, Epsolay, Oracea |
| Genzyme Corporation | $367.84 | 2022-2025 | |
| Lilly USA, LLC | $269.57 | 2022-2025 | Taltz, Ebglyss, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $238.00 | 2022-2024 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $236.11 | 2022-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $186.40 | 2022-2025 | Tremfya |
| Organon LLC | $147.62 | 2025 | Vtama |
| Botanix Sb INC | $142.85 | 2025 | Sofdra |
| Almirall LLC | $113.73 | 2022-2024 | Klisyri, Seysara |
| Incyte Corporation | $100.64 | 2022-2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $99.99 | 2023 | |
| Sun Pharmaceutical Industries INC. | $96.16 | 2024-2025 | |
| Mayne Pharma Commercial LLC | $87.65 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $55.21 | 2025 | Zoryve |
| Biofrontera INC. | $36.11 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $25.44 | 2025 | |
| Epi Health, LLC | $24.22 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $16.28 | 2023 | Arazlo |
| Currax Pharmaceuticals LLC | $14.54 | 2021 | |
| Verrica Pharmaceuticals INC. | $13.75 | 2025 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Behnen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.